![STOCKTALK CENTRAL SPECIAL ALERT]() |
| NEWS ALERT! |
| Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) |
Near Term Price Projection: $.22 |
|
| SHARES OUTSTANDING: |
145.2 million |
| APPROX. FLOAT: |
50 million |
| Near Term Price Proj.: |
$.22 |
|
| A Few Reasons To Own JRSE |
|
- JRSE'S Family Of Resonators Offers Open Door To MULTI-BILLION DOLLAR MARKETS.
- JRSE Is Forecasting Upwards Of $650,000 In Revenues For 2004.
- JRSE Is Forecasting An Increase In Revenues To OVER $6 Million Dollars For Fiscal 2005.
- JRSE Is Seeking Clearance From The FDA To Utilize JACOBSON RESONATORS For Relaxation Purposes Is Looking To Eventually Take An Estimated 3% Of The Leisure/SPA Arena.
- JRSE Is Looking To Penetrate 3% TO 5% OF THE $300+ Billion Dollar Worldwide Chronic Pain Market Segment Within Ten Years.
- JRSE Commits To Achieve 3% To 5% Of The $11+Billion Dollar VETERINARY MEDICINE MARKET Space Within Ten Years.
- JRSE's Licensee in Canada Has Received Regulatory Clearance for the Reduction of Pain Associated with Arthritic Conditions.
- JRSE's Licensee in Europe Has Received European CE-Mark Approval for the Treatment of Pain Associated with Arthrosis of the Knee.
- JRSE'S FIRST INTERNATIONAL TREATMENT CENTER SHOULD BEGIN OPERATIONS IN NASSAU, BAHAMAS IN THE 4TH QUARTER OF 2003.
|
|
JRSE SUBMITS APPLICATION TO THE FDA FOR PERMISSION TO USE RESONATOR SYSTEM FOR RELAXATION; SPA INDUSTRY POTENTIAL LUCRATIVE MARKET SPACE BOYNTON BEACH, FLORIDA, November 12, 2003 (PRIMEZONE) - Harvey Grossman, President and Chief Operating Officer of Jacobson Resonance Enterprises, Inc. (OTC BB: JRSE-OB - News) announces today that JRSE has submitted a 513(g) application with the FDA for non-medical use of our patented technology. Specifically, with this submission we are seeking permission to use Jacobson Resonance in the form of extremely weak but unchanging physiologic magnetic fields for a "Non-Invasive Resonator System For Relaxation."
The type of magnetic fields that we are proposing to use is essentially qualitatively identical to the permanent steady magnets that are sold over-the-counter throughout the world, with only one significant difference. Jacobson Resonance magnetic fields are millions of times weaker than the permanent steady magnets being sold in the marketplace.
Quoting Dr. Jerry I. Jacobson: "Magnetism associated with permanent magnets has been used freely throughout the world for many years. Magnetic fields that do not change polarity, i.e. possessing no frequency alternation, have been considered perfectly safe for human use because they do not induce electrical energies produced by changing magnetic fields. One can find such magnets in department stores in the form of footpads, mattresses, bracelets, necklaces and in systems where an array of magnets may be held about various parts of the body for extended periods of time. Magnets have been known to produce feelings of relaxation. Thus, from a non-medical point of view, we desire to use magnetic fields of a static nature (just as permanent magnets) to produce feelings of relaxation, yet with the kinds of magnetic fields naturally produced by the body. These fields are actually millions of times weaker than the permanent magnets commonly used. Based upon data gleaned from clinical studies in Europe and Canada the observed effects have been reported to be analogous to the permanent magnets while the approach is more natural."
Illustration: Upon receiving permission from the FDA to use our resonator system for relaxation purposes JRSE would then have the potential to enter into the multi-billion dollar Spa industry. In fact, according to the International Spa Association (ISPA) 2002 Spa Industry survey there are 9,632 spas in the United States and approximately 1,300 spas in Canada. The total revenue for the Spa industry has doubled in two years (114 percent increase). In 1999, total revenue was $5 billion, and in 2001 it increased to $10.7 billion. Fifty-one percent of the industry revenue is from treatment rooms and forty-nine percent of treatment room revenue is from massage. The number of spa locations has doubled every four years and spa industry revenues have even surpassed box office gross receipts and amusement/theme park revenues.
Once again it should be noted that JRSE has just submitted the application to the FDA seeking permission for relaxation purposes. As with all submissions to the FDA it is a process that takes at least a few months before a decision is made and there are no assurances that permission will be granted. However, if granted JRSE will then aggressively enter the Spa and Leisure sector and make every effort to tap into this multi-billion dollar market space.
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements.
SOURCE: Jacobson Resonance Enterprises, Inc.
|
|
|
In our opinion, nothing can be more exiting than a Biotech or Bio-Medical Company. Biotech Company's by definition are R&D Company's trying to find cures for various human diseases.
Biotech Company's start off in stages, first identifying a disease, the market for it and developing the cure. These companies once they have gained an FDA approval for their product generally team with Larger Distribution Company's to market their products. Whenever these small Biotech Company's gain an FDA approval for their product, the stock, if publicly traded generally ROCKETS in price.
In the case of JRSE, what we have here is company that has just about been left for dead by Wall Street, in our opinion, Under Followed and Overlooked.
In fact, according to a recent JRSE PR, as Quoted by JRSE's President "We believe that our business model for 2004 and 2005 is important and acts as a launching pad for subsequent success.
Once revenues begin, JRSE is projecting 2005 revenues to approximate Greater Than $6 Million Dollars.
According to Multex, for those Biotech Company's that generate revenues and earnings on a price to sales ratio and price earnings ratio, Biotech's trade in the market at 10.43 times sales and 42.28 times earnings.
As stated earlier JRSE is Projecting $6 Million Dollars in Revenue for Fiscal Year 2005. If over the Near-Term, JRSE were to meet their Recent Guidance, and was Valued at a 50% Discount to its Peers, then applying the Price to Sales (TTM) multiple of 5.22 times (10.43 times 50%), would equate to a market cap of $31.32 Million Dollars.
Thus, when applying the comparative group's price to sales multiples to JRSE we can arrive at a relative valuation of $0.22 Per Share over the Near-Term.
Don't Laugh at a Potential $31 Million Dollar Valuation, do a little Due Diligence as we have and you will find many Biotech Company's Being Valued Significantly By the Market.
Take a look at AGEN, trades on the Nasdaq National Market, never made money, TTM Revenues $3.4 Million and a $400 Million Dollar Market Cap or take a Look at LORFF, trades on the OTCBB, No Revenues and a $127 Million Dollar Market Cap. So Go Figure!
One never knows, JRSE could be one of Wall Streets best kept secrets, but maybe the cat is now coming out of the bag and the timing of this new Investor Awareness Campaign could be good timing in regards to new PR forthcoming to maybe Rocket the stock or maybe it is just another Investor Awareness Campaign.
One never knows, but keep a watchful eye on JRSE near term and as always Watch This Stock Trade.
|
|
|
As We Have Said On Other Occasions:
With JRSE Trading Today for Pennies on the Dollar, One Way to Look at JRSE is as a Perpetual Call Option on the Future Success of the Company. In our Opinion, the risk in Owning JRSE is no Greater Than Owning an Out of the Money Six Month Call Option on Intel, Cisco, or Microsoft. You may lose all or some of your money or you Could Make a Killing.
|
|
|
Are you a CEO of a Public Company or the Head of an Investor Relations or Public Relations Firm interested in Advertising your Company, or do you have a Product or Service that you would like Advertised to what we believe is the most Qualified & Largest Permission Based Opt-in Membership in the World, demographically speaking.
Unlike any other Email Marketer in the World, we can Guarantee Your Advertisement to be Opened and Read by over 1 Million of our Membership within 12 Hours of when we start to send Emails. We believe no other Email Marketer in the World can make this claim.
Yes, that’s right Guaranteed and Verified by what we believe is the Most Sophisticated Tracking Software in the World. Don’t be confused with other offers to Send Million’s of Emails as opposed to our offer whereby over 1 Million of our Members actually Open and Read Your Advertisement within 12 Hours of when we start to send emails, and many more thereafter.
We Don’t Come Cheap! We charge a premium for our services. So, only serious inquiries need to reply. If you are interested in learning more about our services, please click here and provide us with your contact information and some detail of what you are looking to advertise. If we are interested one of our representative’s will contact you shortly.
|
Disclaimer:
The purpose of this advertisement is to provide publicity for the advertised company, its products or services. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. StockTalk Central, and affiliates (STC), publishes reports providing information on selected companies that STC believes has investment potential. STC is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The above report is the opinion of STC and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. STC accepts no liability for any loss arising from an investor's reliance on or use of this report. An investment in JRSE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. An affiliate of STC has been hired by the company for the publication and circulation of this report, and received four million free trading shares of common stock of JRSE by a third party non-affiliate (Inv Mgmt) and STC and affiliates have no relationship to the third party. STC intends to sell all or a portion of the JRSE stock at or about the time of publication of this report. Subsequently STC may buy or sell shares of JRSE stock in the open market. Since an affiliate of STC has been compensated there is an inherent conflict of interest. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. For further details concerning these risks and uncertainties, see the SEC filings of JRSE including the company's most recent annual and quarterly reports.
|
|
|
